EMEA-001147-PIP01-11-M05

Key facts

Invented name
Tafinlar
Active substance
Dabrafenib (mesilate)
Therapeutic area
Oncology
Decision number
P/0260/2017
PIP number
EMEA-001147-PIP01-11-M05
Pharmaceutical form(s)
  • Capsule, hard
  • dispersible tablet
Condition(s) / indication(s)
  • Treatment of solid malignant tumours (excluding melanoma)
  • Treatment of melanoma
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating